Melanotan II: Mechanism, Safety Risks, and Status — Superpower

Understand what your peptides results really mean

See your biomarkers in context with a comprehensive panel.

CLIA-certified labs

HIPAA compliant

Personalized health protocol

Key takeaways

Regulatory Status: As of April 2026, Melanotan II is not FDA-approved for any indication and has never received regulatory approval in any jurisdiction. The MHRA issued a public warning in 2009. The FDA has issued warning letters to domestic distributors. It is not classified as a bulk drug substance eligible for compounding.

Research Stage: Limited early-phase human data from small pilot studies conducted in the 1990s and 2000s; no completed Phase III efficacy or safety trials. Safety signals from case reports published through 2025.

Availability: Not legally marketed for human use. Superpower does not offer this substance. Products sold online as "research use only" are unregulated.

What it is: A synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates all four peripheral melanocortin receptors non-selectively.

What the evidence actually shows: Small human studies confirmed skin tanning and erection induction alongside dose-limiting nausea and flushing; multiple published case reports associate use with melanoma, dysplastic nevus eruption, priapism requiring surgery, rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome (PRES). As of April 2026, no completed human safety or efficacy trial has been published.

Compound reference data: PubChem CID 2656580

Where melanotan II comes from and how it works

Origin and discovery

Melanotan II was developed at the University of Arizona in the late 1980s and early 1990s as a candidate chemopreventive agent: the hypothesis was that controlled induction of melanogenesis might reduce UV-induced DNA damage and skin cancer risk. The compound is a synthetic, cyclized analog of [Nle4,D-Phe7]-α-MSH, a superpotent linear melanotropin first characterized in a 1980 paper by Sawyer, Sanfilippo, Hruby, and Hadley in the Proceedings of the National Academy of Sciences, reported to be approximately 26 times more potent than native α-MSH in the mouse melanoma adenylate cyclase assay and resistant to enzymatic degradation by serum proteases. MT-II introduced a lactam bridge that further stabilized the peptide backbone against proteolysis, increasing both potency and receptor residence time. It does not occur naturally in the body; it is a laboratory-synthesized research compound.

Proposed mechanism: Non-selective melanocortin receptor agonism

The melanocortin system comprises five G-protein-coupled receptors (MC1R through MC5R), each with distinct tissue expression and physiological roles. Native α-MSH shows preferential activity at MC1R, which is located on melanocytes and mediates eumelanin synthesis. Melanotan II is a non-selective agonist: it binds and activates MC1R, MC3R, MC4R, and MC5R with broadly comparable affinity. That non-selectivity is clinically significant because the effects observed in the small human studies conducted in the 1990s were not limited to pigmentation. MC4R activation in the hypothalamus and spinal cord drives erection and sexual arousal. MC3R and MC5R activation produces a range of autonomic effects including suppression of appetite, altered cardiovascular tone, and changes in exocrine secretion. The erection effect was not anticipated during the drug's original development as a tanning agent — it emerged as an adverse finding in the first human pilot trial and subsequently redirected research toward sexual dysfunction as a secondary indication. The mechanism underlying pigmentation, which is the reason most users self-administer the compound, is activation of MC1R on melanocytes, triggering the cAMP-PKA signaling cascade that upregulates tyrosinase and drives production of eumelanin (brown-black pigment) rather than phaeomelanin (yellow-red pigment).

What the early human research showed

The foundational human study was a 1996 pilot trial in Life Sciences by Dorr and colleagues, in which three healthy male volunteers received subcutaneous MT-II at escalating doses. The study confirmed dose-dependent skin tanning but also documented dose-limiting nausea, flushing, and spontaneous penile erections as the primary adverse effects. A subsequent preformulation and stability study by Lan, Ugwu, and colleagues, published in the Journal of Pharmaceutical Sciences in 1994, characterized the physicochemical properties of melanotan-II as a candidate skin-cancer chemopreventive peptide. Separate human pharmacokinetic work by Ugwu, Blanchard, and colleagues, published in Biopharmaceutics and Drug Disposition in 1997, characterized the linear analog melanotan-I, demonstrating complete subcutaneous bioavailability and pigmentation lasting more than three weeks after a single dose — a useful contrast to the cyclic, non-selective MT-II. These studies were conducted in the context of cancer prevention research, not as a basis for consumer self-administration. No Phase III trials were ever conducted. The compound was never submitted for FDA approval, and its subsequent circulation as a gray-market injectable product was not the outcome its developers intended.

The sexual function lineage: MT-II and bremelanotide

The unexpected erectile response observed in the 1996 pilot trial led to a formal research program at the University of Arizona. A 1998 double-blind, placebo-controlled crossover study by Wessells and colleagues in 10 men with psychogenic erectile dysfunction in the Journal of Urology reported that MT-II produced clinically apparent erections in 8 of 10 participants versus 0 of 10 on placebo, with mean tip rigidity exceeding 80% and erections lasting a mean of 38 minutes. A follow-on double-blind, placebo-controlled crossover study published in Urology in 2000 enrolled 10 men with organic erectile dysfunction — including those with diabetes, hypertension, and post-prostatectomy status — each of whom received two active (MT-II 0.025 mg/kg subcutaneous) and two placebo injections; subjectively reported erections occurred after 12 of 19 MT-II injections versus 1 of 21 placebo injections, mean rigidity scores reached 6.9/10 among responders, and duration of tip rigidity >80% averaged 45.3 vs 1.9 minutes (p = 0.047), with 4 of 19 active-drug injections producing severe nausea — a small, short-observation cohort that provided proof-of-concept rather than confirmatory efficacy data. A review synthesizing these data, published in the International Journal of Impotence Research in 2000, established that MT-II acts centrally through hypothalamic MC4R signaling — a mechanism mechanistically distinct from phosphodiesterase-5 inhibitors, which act peripherally via the nitric oxide and cyclic GMP pathway in corporal tissue.

This research ultimately contributed to the development of bremelanotide (PT-141), an N-acetylated cyclic analog of MT-II. Bremelanotide completed the full Phase III clinical trial program and received FDA approval in June 2019 as Vyleesi, indicated for hypoactive sexual desire disorder in premenopausal women. The pivotal RECONNECT Phase III program, reported by Kingsberg and colleagues in Obstetrics and Gynecology in 2019, comprised two identical 24-week double-blind placebo-controlled trials (Studies 301 and 302) enrolling a combined 1,267 premenopausal women with HSDD; bremelanotide 1.75 mg administered subcutaneously as needed produced integrated improvements of +0.35 on the Female Sexual Function Index Desire domain (p < 0.001) and −0.33 on Female Sexual Distress Scale item 13 (p < 0.001) versus placebo, with nausea, flushing, and headache each reported in ≥10% of bremelanotide recipients — the only completed regulatory trial data in this mechanistic class. This comparison is for scientific context only: bremelanotide and Melanotan II have fundamentally different regulatory statuses, evidence bases, and safety profiles. Melanotan II has never undergone the regulatory review process that bremelanotide completed, and the two compounds should not be conflated.

Thanks for signing up!

Check your inbox — your first issue is on the way. We send clinically reviewed health science, never spam.

Melanotan II vs. melanotan I (afamelanotide): Key differences

The two compounds are structurally related but clinically distinct. Melanotan I is the linear (non-cyclized) analog of [Nle4,D-Phe7]-α-MSH, now known as afamelanotide. Unlike MT-II, afamelanotide has high selectivity for MC1R and does not significantly activate MC4R at therapeutic doses, which means it produces pigmentation without the erection, nausea, and autonomic effects that characterize MT-II. Afamelanotide completed a full regulated clinical development program: a 2021 focused review by Wensink, Wagenmakers, and colleagues in Expert Review of Clinical Pharmacology summarizes the Phase III RCT evidence base (studies CUV029, CUV030, and CUV039) that supported FDA approval of afamelanotide as Scenesse in October 2019 for phototoxic reactions in adults with erythropoietic protoporphyria. A 2016 drug review by Kim and Garnock-Jones in the American Journal of Clinical Dermatology also covers the afamelanotide evidence base and confirms the drug's narrow approved indication. As of April 2026, afamelanotide is the only MC1R-targeted melanocortin agonist with FDA approval for any indication. Melanotan II has no approved indication anywhere in the world. The existence of an approved, selective MC1R agonist developed through rigorous clinical trials makes the continued gray-market use of the non-selective, unapproved MT-II particularly difficult to justify on grounds of mechanism alone.

Safety: The published case evidence

Nevi changes and melanoma risk

The most clinically consequential safety signals associated with MT-II involve melanocytes: the same cells the compound is intended to stimulate. Multiple published case reports document new nevus formation, rapid darkening and growth of existing nevi, dysplastic nevus eruption, and melanoma following MT-II use.

A 2014 report by Schulze, Erdmann, and colleagues in the European Journal of Dermatology documented that a single mono-dose subcutaneous MT-II injection produced eruptive naevi and darkening of pre-existing naevi within 24 hours — establishing that visible melanocytic changes can occur after one exposure. A 2009 case report by Cardones and Grichnik in the Archives of Dermatology documented a 40-year-old man with a prior melanoma and dysplastic nevus syndrome who self-administered synthetic α-MSH and developed eruptive atypical nevi plus growth of pre-existing nevi, which lightened and regressed after discontinuation — providing mechanistic evidence that synthetic melanocortin agonists can drive proliferation of neoplastic melanocytes in predisposed individuals. A 2012 report by Sivyer and Rosendahl in Dermatology Practical and Conceptual described a 16-year-old girl with familial atypical multiple mole melanoma syndrome who developed dysplastic nevus changes after two months of daily MT-II combined with sunbed use, illustrating the risk in individuals with genetic melanoma predisposition.

On melanoma specifically: A 2012 case report by Ong and colleagues in the Australasian Journal of Dermatology documented melanoma in situ arising in a nevus that darkened and enlarged during MT-II self-injection. A 2014 case by Hjuler and Lorentzen in Dermatology described cutaneous melanoma on the gluteal region in a 20-year-old Fitzpatrick-II woman following MT-II use combined with tanning-bed exposure. A case series by Paurobally and colleagues in the British Journal of Dermatology in 2011 documented multiple cases of dysplastic nevus eruption and malignant melanoma associated with MT-II use, concluding that "the harmlessness of melanotan should not be promoted" until its effects on melanocyte proliferation and carcinogenesis have been adequately characterized. A 2025 case report by Yassin Alsabbagh, Bhujel , and colleagues in the International Journal of Oral and Maxillofacial Surgery extends the melanoma signal to mucosal sites, describing a 22-year-old otherwise healthy woman who developed an anterior maxillary mucosal malignant melanoma after using MT-II nasal spray for tanning — indicating that the oncogenic risk may not be confined to injection routes or cutaneous sites.

A comprehensive 2017 review by Habbema and colleagues in the International Journal of Dermatology catalogued the full spectrum of reported MT-II harms — melanoma, nevus change, gastrointestinal, cardiovascular, and central nervous system events — and drew an explicit distinction between afamelanotide's regulated clinical development and MT-II's black-market status, concluding that the two compounds should not be treated as equivalent. A 2022 Dutch-language clinical review by Eijmael, Janmaat , and colleagues in Nederlands Tijdschrift voor Geneeskunde documented the tanning-related risks of melanotan ("Barbie drug") products in the European context, including pigmentation changes and dysplastic naevi.

Priapism

Because MT-II activates MC4R-driven erection pathways non-selectively, prolonged and pathological erection is a documented risk. A 2013 case report by Devlin and colleagues in Clinical Toxicology documented MT-II overdose associated with priapism, representing the first formal priapism signal in the literature. A 2019 case by Dreyer and colleagues in BMJ Case Reports described low-flow ischemic priapism following abdominal subcutaneous MT-II injection, managed with cavernosal aspiration and intracavernosal phenylephrine, with the patient having not recovered erectile function at four-week follow-up. A 2021 case report by Mallory and colleagues in Sexual Medicine documented acute ischemic priapism after MT-II injection that required penoscrotal decompression surgery after failed cavernosal aspiration and phenylephrine irrigation. These reports collectively demonstrate that the MC4R-mediated erectogenic effect that made MT-II interesting to researchers can progress to an irreversible surgical emergency in users who self-inject gray-market product.

Rhabdomyolysis and cardiovascular toxicity

A 2012 emergency-department case report by Nelson and colleagues in Clinical Toxicology documented a 39-year-old man who injected six milligrams of subcutaneous MT-II — six times a commonly cited starting dose — and developed systemic sympathomimetic toxicity with tachycardia, mydriasis, diffuse muscle tremors, and rhabdomyolysis. This case illustrates the consequence of dose variability in gray-market products: a vial labeled 10 mg that contains 8 mg, divided into doses using a syringe calibrated for insulin, produces dosing that is neither predictable nor safe. An independent laboratory analysis by Breindahl and colleagues, published in Drug Testing and Analysis in 2015, analyzed MT-II vials purchased from three online shops — each labeled as containing 10 mg — and found that actual peptide content ranged from 4.32 to 8.84 mg, with every vial below the claimed dose; vials from two shops contained unknown impurities at 4.1–5.9% by mass, while vials from the third were below the limit of quantification, providing quantitative evidence that gray-market MT-II is systematically underdosed and variably contaminated. A parallel 2018 review by Callaghan in Dermatology Online Journal mapped the underground melanotan supply chain, user sourcing practices, and purity patterns, adding further context for the regulatory and safety picture.

Renal and central nervous system events

The first published case of MT-II-associated renal infarction, reported by Peters and colleagues, appeared in CEN Case Reports in 2020, proposing both thrombotic and direct nephrotoxic mechanisms. A 2013 case report by Kaski and colleagues in Annals of Internal Medicine linked MT-II use to posterior reversible encephalopathy syndrome (PRES), a condition characterized by seizures, visual disturbance, and bilateral posterior white-matter abnormalities on MRI — extending the documented safety picture to the central nervous system and its vascular architecture.

Regulatory and legal status

FDA status

As of April 2026, Melanotan II has no FDA approval for any indication and has never been submitted for review. It is not classified as a Category 1 bulk drug substance eligible for compounding under Section 503A. The FDA has issued warning letters to domestic distributors of MT-II. It is not legally marketed for human use in the United States in any form or formulation.

MHRA warning (united kingdom)

The UK Medicines and Healthcare products Regulatory Agency issued a public warning about melanotan products in 2009, discussed in a 2009 BMJ clinical commentary by Langan, Ramlogan, and colleagues that specifically noted the link between MT-II use and mole changes. The MHRA classified MT-II as an unlicensed medicine and stated that its safety had not been established. The compound remains unlicensed in the United Kingdom as of April 2026.

What this means practically

Products labeled as Melanotan II or MT-II sold through online vendors and gray-market sources are not regulated. They are not manufactured under pharmaceutical GMP standards, are not tested for purity or potency by any regulatory body, and have no established dosing guidance validated in human safety trials. The Breindahl 2015 analytical study found that labeled doses were inaccurate in every sample tested. Users have no reliable way to know what dose they are administering, whether the vial contains the compound it claims to contain, or what impurities are present. There is no legal pathway to obtain pharmaceutical-grade Melanotan II for human use in the United States, the United Kingdom, or any jurisdiction where the compound has been subject to regulatory scrutiny.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Who should not use melanotan II

The short answer: no one, outside an IRB-approved clinical research study. Melanotan II has no FDA approval, has never been submitted for regulatory review in any jurisdiction, is not eligible for pharmaceutical compounding, and has a published case literature documenting melanoma, dysplastic nevus eruption, ischemic priapism requiring surgical decompression, rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome. There is no population for whom use of this compound is supported by evidence.

Several mechanistic and case-documented considerations are of particular concern. These are illustrative, not a contraindication checklist — there is no contraindication table because there is no approved indication:

Personal or family history of melanoma — MC1R activation stimulates melanocyte proliferation; the Cardones and Grichnik (2009) case report documents neoplastic melanocyte proliferation after short-term synthetic α-MSH exposure in individuals with melanoma history or dysplastic nevus syndrome

Multiple atypical or dysplastic nevi — published case reports document rapid darkening, enlargement, and malignant transformation of pre-existing nevi within 24 hours of a single injection

Familial atypical multiple mole melanoma (FAMMM) syndrome — the Sivyer and Rosendahl (2012) case illustrates the mismatch between genetic melanoma predisposition and MC1R stimulation

Any predisposition to priapism or vascular thrombosis — MC4R activation can produce pathological erection; published cases document ischemic priapism progressing to surgical emergency and permanent erectile dysfunction

Cardiovascular disease or elevated blood pressure — autonomic effects mediated by MC3R and MC5R include vasopressor activity; sympathomimetic toxicity has been documented

Pre-existing renal or neurological conditions — case reports document renal infarction and PRES in previously healthy users

Pregnancy or breastfeeding — no human reproductive or developmental toxicology data exists

Athletes subject to anti-doping testing — non-approved peptide hormones and analogs are prohibited under WADA Section S2

Minors — the Sivyer and Rosendahl case involved a 16-year-old; gray-market access creates real exposure in this population

Any product obtained through unregulated online or gray-market channels — independent laboratory analysis has confirmed that labeled doses are systematically inaccurate and that unknown impurities are present

Which biomarkers are relevant if you are exploring melanocortin science?

If someone has been exposed to MT-II or is researching the melanocortin system, understanding their baseline biology provides objective context that no amount of internet research can substitute.

High-sensitivity CRP (hs-CRP): A sensitive marker of systemic inflammation. Relevant as a baseline measure of inflammatory status; elevated values warrant clinical context before introducing any investigational compound.

eGFR (estimated glomerular filtration rate): Measures kidney filtration function. Given published case reports of MT-II-associated renal infarction, renal function baseline is clinically meaningful for any individual who has used or is considering use.

GGT and ALT: Liver enzyme markers that establish hepatic function baseline. Relevant to the metabolism and clearance of investigational peptides and to assessing general safety context.

Hematocrit and hemoglobin: Components of the complete blood count that reflect erythrocyte mass and oxygenation capacity. Rhabdomyolysis (documented in the Nelson 2012 case) produces secondary effects on renal handling of myoglobin, and a CBC baseline provides the context to interpret post-exposure changes.

Creatinine (via the creatinine test): Measures kidney waste clearance. A baseline creatinine, interpreted alongside eGFR, provides the reference point needed to identify acute renal injury.

White blood cells (WBC): A general immune activity marker. Infectious contamination from non-sterile gray-market injectables can produce an acute inflammatory response; baseline WBC provides context for evaluating post-injection symptoms.

Biomarkers relevant to cutaneous melanoma surveillance: A practical guide to melanoma biomarkers provides clinical context for individuals who have been exposed to compounds with documented melanocyte-stimulating activity and who want to understand what objective markers are clinically relevant.

When to take this seriously

If you have used Melanotan II and have noticed new moles, changes in existing moles (darker color, irregular borders, rapid growth), or skin changes in any location including mucosal sites, see a dermatologist. This is not precautionary: the published case literature documents melanoma arising in individuals with no prior melanoma history following MT-II use. Pigment changes that develop or accelerate during or after use warrant clinical evaluation regardless of the person's baseline skin type or perceived UV exposure history. The same applies to urological symptoms: prolonged erection following MT-II injection requires emergency medical evaluation; ischemic priapism becomes an irreversible condition within hours.

More broadly, the melanocortin system is not well understood at the level of individual variation. MC1R genotype modulates the pigmentation response, as a 2006 study by Fitzgerald, Fryer, and colleagues in Peptides established — documenting heterogeneous melanin-synthesis responses to [Nle4, D-Phe7]-α-MSH in humans carrying MC1R variant alleles. Who responds to MT-II with tumor-promoting melanocyte proliferation versus unremarkable tanning is not predictable from any currently available consumer test. That uncertainty, combined with the absence of any approved safety data, is the biological argument for leaving gray-market MC receptor agonism alone. That commitment to understanding biology before making decisions about it is what drives Superpower's approach to preventive health: objective biomarker data and clinical context come before every health decision, especially those involving compounds with limited human evidence and documented serious risks.

IMPORTANT SAFETY INFORMATION

Melanotan II (MT-II) is not FDA-approved for any indication and has never received regulatory approval in any jurisdiction. As of April 2026, it is not eligible for pharmaceutical compounding under Section 503A or 503B. Superpower Health does not prescribe, sell, compound, or facilitate access to Melanotan II. This article is provided solely for educational and informational purposes.

Documented serious risks in the published case literature include: cutaneous melanoma (multiple case reports), dysplastic nevus eruption and rapid nevus darkening (including within 24 hours of single-dose injection), oral mucosal malignant melanoma (case report, 2025), ischemic priapism requiring surgical decompression and associated with permanent erectile dysfunction (multiple case reports), rhabdomyolysis and sympathomimetic toxicity (emergency case report), renal infarction (case report), and posterior reversible encephalopathy syndrome (PRES) with seizures and white-matter abnormalities on MRI (case report).

Gray-market products labeled as Melanotan II are not manufactured under pharmaceutical standards. Independent laboratory analysis has confirmed that peptide content in online-sold vials ranges from 4.32 to 8.84 mg in vials labeled as 10 mg, with measurable unknown impurities. Dosing cannot be reliably controlled.

Melanotan II should not be used by anyone outside an IRB-approved clinical research study. No FDA-approved indication, label, or human dosing protocol exists. Populations of particular concern based on documented case literature and mechanism include: individuals with personal or family history of melanoma; individuals with dysplastic nevus syndrome or FAMMM syndrome; individuals with active cardiovascular, renal, or neurological disease; individuals with any predisposition to priapism or vascular thrombosis; pregnant or breastfeeding individuals; minors; and athletes subject to WADA-compliant testing. These are illustrative concerns, not a contraindication checklist — there is no approved indication.

As of the 2026 WADA Prohibited List, non-approved peptide hormones and their analogs are prohibited under Section S2. Competitive athletes should consider MT-II prohibited.

If you have used Melanotan II and have noticed pigment changes, seek dermatological evaluation. If you experience a prolonged erection following MT-II injection, seek emergency medical care immediately.

Frequently Asked Questions

Is Melanotan II FDA-approved?

No. Melanotan II has never been submitted for FDA approval and holds no regulatory approval in any jurisdiction as of April 2026. It is not classified as a bulk drug substance eligible for pharmaceutical compounding. Products sold online as research use only are unregulated and have no legal pathway to human use in the United States.

Is Melanotan II legal in the United States?

It is not legally marketed for human use. The FDA has issued warning letters to domestic distributors. No prescription can be written for it because it has no approved indication and is not eligible for compounding. Possession may not trigger the same legal exposure as a scheduled drug, but the sale of MT-II for human use is not permitted under current FDA regulations.

Can a doctor prescribe Melanotan II?

No. A licensed physician cannot write a valid prescription for Melanotan II in the United States. There is no approved indication, no FDA-reviewed prescribing information, and no compounding pharmacy pathway. Any product labeled as MT-II that is sold online or through gray-market channels exists outside the regulated pharmaceutical system entirely.

Can Melanotan II cause cancer?

The published case literature includes multiple reports of melanoma arising in individuals who used MT-II. It is not possible to establish causation from case reports alone; however, the mechanism is biologically plausible: MC1R activation stimulates melanocyte proliferation, and in individuals with pre-existing dysplastic nevi or genetic melanoma predisposition, that stimulation may drive neoplastic transformation. A 2025 case report by Yassin Alsabbagh, Bhujel, and colleagues also documents a possible association with oral mucosal malignant melanoma, extending the signal beyond cutaneous sites. These signals have not been dismissed by dermatology literature; they are cited as the primary reason regulators have issued warnings.

What is the difference between Melanotan II and Melanotan I?

Melanotan I (afamelanotide, brand name Scenesse) is a linear peptide with high selectivity for MC1R; it received FDA approval in October 2019 for phototoxic reactions in erythropoietic protoporphyria and completed a full Phase III clinical trial program. Melanotan II is a cyclized peptide that activates MC1R, MC3R, MC4R, and MC5R non-selectively; it has never been submitted for FDA approval and produces a substantially broader range of effects including erection, nausea, flushing, and the documented safety signals described above. These are distinct compounds with fundamentally different regulatory statuses and evidence bases.

What is the difference between Melanotan II and PT-141 (bremelanotide)?

PT-141 (bremelanotide, brand name Vyleesi) is an N-acetylated cyclic analog of MT-II that was specifically developed from MT-II's erection-inducing effect and taken through the full FDA approval process. Bremelanotide received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women based on the pivotal RECONNECT Phase III trials. MT-II is the unapproved precursor compound from which bremelanotide's development lineage originates. They are different molecules with different regulatory statuses and are not interchangeable.

Are peptides legal again in 2026 following the FDA reclassification?

The February 2026 FDA policy developments primarily concerned the compounding status of certain bulk drug substances. Melanotan II was not affected: it was not eligible for compounding before those developments and remains ineligible after them. The reclassification that expanded access to some peptides in compounding pharmacies does not apply to MT-II, which has never been on any list of approved bulk drug substances and has been the subject of FDA warning letters targeting its distribution.

What mole changes should concern someone who has used Melanotan II?

Any new mole, any darkening or enlargement of an existing mole, irregular borders, color heterogeneity, or any mole that has changed in size or shape during or after MT-II use warrants evaluation by a dermatologist. The Schulze 2014 case report documents eruptive naevi and darkening within 24 hours of a single injection; the Ong 2012 and Hjuler 2014 case reports document melanoma following use. There is no safe interval to wait before seeking evaluation of pigment changes in this context.

References

PubChem (National Library of Medicine). (n.d.). *CID 2656580*. https://pubchem.ncbi.nlm.nih.gov/compound/2656580

Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME (1980). 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. *Proceedings of the National Academy of Sciences of the United States of America*, *77*(10), 5754-8. https://doi.org/10.1073/pnas.77.10.5754

Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. *Life sciences*, *58*(20), 1777-84. https://doi.org/10.1016/0024-3205(96)00160-9

Lan EL, Ugwu SO, Blanchard J, Fang X, Hruby VJ, Sharma S (1994). Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. *Journal of pharmaceutical sciences*, *83*(8), 1081-4. https://doi.org/10.1002/jps.2600830805

Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, Aickin M, Hruby VJ (1997). Skin pigmentation and pharmacokinetics of melanotan-I in humans. *Biopharmaceutics & drug disposition*, *18*(3), 259-69. https://doi.org/10.1002/(sici)1099-081x(199704)18:3&lt;259::aid-bdd20&gt;3.0.co;2-x

Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. *The Journal of urology*, *160*(2), 389-93. https://pubmed.ncbi.nlm.nih.gov/9679884/

Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. *Urology*, *56*(4), 641-6. https://doi.org/10.1016/s0090-4295(00)00680-4

Wessells H, Levine N, Hadley ME, Dorr R, Hruby V (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. *International journal of impotence research*, *12 Suppl 4*, S74-9. https://doi.org/10.1038/sj.ijir.3900582

Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. *Obstetrics and gynecology*, *134*(5), 899-908. https://doi.org/10.1097/AOG.0000000000003500

Wensink D, Wagenmakers MAEM, Langendonk JG (2021). Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. *Expert review of clinical pharmacology*, *14*(2), 151-160. https://doi.org/10.1080/17512433.2021.1879638

Kim ES, Garnock-Jones KP (2016). Afamelanotide: A Review in Erythropoietic Protoporphyria. *American journal of clinical dermatology*, *17*(2), 179-85. https://doi.org/10.1007/s40257-016-0184-6

Schulze F, Erdmann H, Hardkop LH, Anemüller W, Rose C, Zillikens D, Fischer TW (2014). Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. *European journal of dermatology : EJD*, *24*(1), 107-9. https://doi.org/10.1684/ejd.2013.2227

Cardones AR, Grichnik JM (2009). alpha-Melanocyte-stimulating hormone-induced eruptive nevi. *Archives of dermatology*, *145*(4), 441-4. https://doi.org/10.1001/archdermatol.2008.623

Sivyer GW (2012). Changes of melanocytic lesions inducedby Melanotan injections and sun bed use ina teenage patient with FAMMM syndrome. *Dermatology practical & conceptual*, *2*(3), 203a10. https://doi.org/10.5826/dpc.0203a10

Ong S, Bowling J (2012). Melanotan-associated melanoma in situ. *The Australasian journal of dermatology*, *53*(4), 301-2. https://doi.org/10.1111/j.1440-0960.2012.00915.x

Hjuler KF, Lorentzen HF (2014). Melanoma associated with the use of melanotan-II. *Dermatology (Basel, Switzerland)*, *228*(1), 34-6. https://doi.org/10.1159/000356389

Paurobally D, Jason F, Dezfoulian B, Nikkels AF (2011). Melanotan-associated melanoma. *The British journal of dermatology*, *164*(6), 1403-5. https://doi.org/10.1111/j.1365-2133.2011.10273.x

Yassin Alsabbagh A, Bhujel N, Singh RP (2025). Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. *International journal of oral and maxillofacial surgery*, *54*(9), 806-808. https://doi.org/10.1016/j.ijom.2025.03.014

Habbema L, Halk AB, Neumann M, Bergman W (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. *International journal of dermatology*, *56*(10), 975-980. https://doi.org/10.1111/ijd.13585

Eijmael MJPM, Janmaat CJ, Briët-Schipper EMN (2022). [The risks of tanning with the Barbie drug]. *Nederlands tijdschrift voor geneeskunde*, *166*. https://pubmed.ncbi.nlm.nih.gov/35736369/

Devlin J, Pomerleau A, Foote J (2013). Melanotan II overdose associated with priapism. *Clinical toxicology (Philadelphia, Pa.)*, *51*(4), 383. https://doi.org/10.3109/15563650.2013.784775

Dreyer BA, Amer T, Fraser M (2019). Melanotan-induced priapism: a hard-earned tan. *BMJ case reports*, *12*(2). https://doi.org/10.1136/bcr-2018-227644

Mallory CW, Lopategui DM, Cordon BH (2021). Melanotan Tanning Injection: A Rare Cause of Priapism. *Sexual medicine*, *9*(1), 100298. https://doi.org/10.1016/j.esxm.2020.100298

Nelson ME, Bryant SM, Aks SE (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. *Clinical toxicology (Philadelphia, Pa.)*, *50*(10), 1169-73. https://doi.org/10.3109/15563650.2012.740637

Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A (2015). Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. *Drug testing and analysis*, *7*(2), 164-72. https://doi.org/10.1002/dta.1655

Callaghan Iii DJ (2018). A glimpse into the underground market of melanotan. *Dermatology online journal*, *24*(5). https://pubmed.ncbi.nlm.nih.gov/30142729/

Peters B, Hadimeri H, Wahlberg R, Afghahi H (2020). Melanotan II: a possible cause of renal infarction: review of the literature and case report. *CEN case reports*, *9*(2), 159-161. https://doi.org/10.1007/s13730-020-00447-z

Kaski D, Stafford N, Mehta A, Jenkins IH, Malhotra P (2013). Melanotan and the posterior reversible encephalopathy syndrome. *Annals of internal medicine*, *158*(9), 707-8. https://doi.org/10.7326/0003-4819-158-9-201305070-00020

Langan EA, Ramlogan D, Jamieson LA, Rhodes LE (2009). Change in moles linked to use of unlicensed 'sun tan jab'. *BMJ (Clinical research ed.)*, *338*, b277. https://doi.org/10.1136/bmj.b277

Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM (2006). Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. *Peptides*, *27*(2), 388-94. https://doi.org/10.1016/j.peptides.2004.12.038